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Summary
Background.— The prognosis for patients aged over 75 years who receive a pacemaker in the
context of sinus node dysfunction is unclear.
Aims.— We sought to evaluate the incidences of atrial ﬁbrillation, heart failure and death in
such patients, and the role of the pacing mode in their prognosis.
Methods.— This was a retrospective study of 102 patients aged over 75 years (mean
82.2± 4.4 years) who received a pacemaker in the context of sinus node dysfunction.
Results.— During the follow-up period (mean 806 days), 36 patients (35.3%) experienced heart
failure, 47 patients (46.1%) had an episode of paroxysmal atrial ﬁbrillation, 19 patients (18.6%)
progressed to chronic atrial ﬁbrillation and 29 (28.4%) died, the fatal event being sudden death
or of cardiac origin in almost half of these patients (44.8%). Patients assigned to dual-chamber
minimal ventricular pacing showed signiﬁcantly lower rates of heart failure episodes (P = 0.023)
and all-cause mortality (P < 0.001) than those assigned to conventional dual-chamber pacing.
In contrast, the two groups did not differ with regard to either paroxysmal or chronic atrial
ﬁbrillation.
Abbreviations: AF, Atrial ﬁbrillation; HF, Heart failure; LVEF, Left ventricular ejection fraction; VKA, Vitamin K antagonist.
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Conclusion.— In patients aged over 75 years, the use of dual-chamber pacemakers incorporating
an algorithm minimizing ventricular pacing for sinus node dysfunction seems to decrease the
number of heart failure episodes and mortality. On the basis of this ﬁnding, the implantation
of such devices seems justiﬁable, even in this age group.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— Le pronostic des patients de plus de 75 ans qui ont bénéﬁcié d’un stimulateur
cardiaque pour une dysfonction sinusale est mal connu.
Objectif.— Le but de cette étude a été d’évaluer dans cette population, les incidences de la
ﬁbrillation auriculaire, de l’insufﬁsance cardiaque et de la mortalité ainsi que l’inﬂuence du
mode de stimulation sur le pronostic.
Méthodes.— Il s’agit d’une étude rétrospective sur 102 patients de plus de 75 ans porteurs d’un
pacemaker pour une dysfonction sinusale.
Résultats.— Au cours du suivi (806 jours en moyenne), 36 patients (35,3 %) ont présenté une
décompensation cardiaque, 47 patients (46,1 %) un épisode de ﬁbrillation atriale paroxystique,
19 patients (18,6 %) sont passés en ﬁbrillation atriale chronique et 29 (28,4 %) sont décédés dont
près de la moitié (44,8 %) de mort subite ou de cause cardiaque. Dans le groupe de patients
porteurs d’un stimulateur double chambre avec un algorithme minimisant la stimulation ven-
triculaire, nous avons observé un taux moindre de décompensations cardiaques (p = 0,023) et
une plus faible mortalité totale (p < 0,001) que dans le groupe de patients ayant un stimulateur
DDD standard. En revanche, il n’y a pas eu de différences entre les deux groupes en termes de
ﬁbrillation auriculaire paroxystique ou chronique.
Conclusion.— Les stimulateurs cardiaques double chambre avec un algorithme minimisant la
stimulation ventriculaire semblent diminuer le nombre d’épisodes de décompensation car-
diaque et les décès chez les patients de plus de 75 ans atteints de dysfonction sinusale. Cela
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ackground
inus node dysfunction is one of the main indications
or pacemaker implantation. However, the prognosis for
atients who receive a pacemaker for this reason, in terms
f mortality and occurrence of atrial ﬁbrillation (AF) or heart
ailure (HF), has not been clearly established in the oldest
ge group.
Large-scale randomized trials, such as MOST [1] and
TOPP [2], did not really demonstrate a great superiority
f dual-chamber pacemakers over single-chamber devices.
t has been shown that dual-chamber pacemakers can be
eleterious compared with single-chamber ventricular pace-
akers when the ventricular stimulation rate is high (MOST
1], DAVID [3]). New algorithms were developed in order to
imit the ventricular stimulation rate. The SAVE PACe [4]
tudy showed a beneﬁt of dual-chamber minimal ventric-
lar pacing over conventional dual-chamber pacing in terms
f persistent AF.
Few patients aged over 75 years were included in
hese trials. However, the population aged over 75 years
orresponds with more than 50% of pacemaker ﬁrst
mplantations [5], and this population is expected to
ncrease threefold within the next 40 years [6]. It there-
ore seemed worthwhile to analyse the outcome of
atients aged over 75 years who had received a pace-
aker in the context of sinus node dysfunction, either
lone or already associated with paroxystic supraventricular
rrhythmia.
t
p
cême à cet âge.
s droits réservés.
ethods
his single-centre, retrospective study, conducted in the
ardiology Department of the Medical, Surgical and Obstet-
ical Centre in Schiltigheim, France, included all consecutive
atients aged over 75 years on the day of pacemaker
mplantation and referred for initial implantation of a pace-
aker in the context of sinus node dysfunction between
January 2001 and 31October 2006. Patients with second-
r third-degree atrioventricular block and those who had
ndergone implantation of a single-chamber ventricular
acemaker were excluded.
The patient’s medical history, clinical characteristics,
acemaker settings and left ventricular ejection fraction
LVEF) at the start of follow-up were extracted from the
nitial hospitalization report. The clinical events occur-
ing during follow-up were recorded on questionnaires sent
o each patient’s cardiologist. The questionnaires were
ompleted with the help of the patient’s primary care physi-
ian and the reports from the centre in which the pacemaker
ad been implanted.
The pacing algorithms considered to be algorithms
inimizing ventricular stimulation rate were MVP®
Medtronic Inc. Minneapolis, MN, USA) and SafeR® (Sorin
roup, Milan, Italy).
The primary endpoints deﬁned before the start of
he study were mortality, episodes of HF, incidences of
aroxysmal and chronic AF and occurrence of embolic
omplications. All episodes of HF were taken into account,
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Table 1 Patient demographics and clinical
characteristics.
Characteristic
Men 33 (32.4)
Women 69 (67.6)
Age (years) 82.2± 4.4
Sinus node dysfunction
without history of AF
45 (44.1)
Sinus node dysfunction with
history of paroxysmal AF
57 (55.9)
LVEF at inclusion (%) 59.3± 10.9
Ischaemic cardiopathy 20 (19.6)
Non-obstructive
cardiomyopathy
4 (3.9)
Valvular disease 20 (19.6)
Left ventricular hypertrophy 36 (35.3)
Other cardiopathy 3 (2.9)
No known cardiopathy 37 (36.3)
History of hypertension 80 (78.4)
History of heart failure 16 (15.7)
History of stroke 17 (16.7)
Diabetes 26 (25.5)
CHADS2 score≥ 2 86 (84.3)
Signs of heart failure at
implantation (Killip
class≥ 2)
26 (25.5)
AF: atrial ﬁbrillation; CHADS2: congestive heart failure, hyper-
tension, age >75 years, diabetes and prior stroke/transient
ischaemic attack; LVEF: left ventricular ejection fraction; SD:
standard deviation.
Table 2 Pacemaker characteristics and pacing mode at
the time of implantation.
Pacemaker characteristic/
pacing mode
Number of patients (%)
Conventional DDD pacing 71 (69.6)
Dual-chamber minimal
ventricular pacing
27 (26.5)
AAI pacing 3 (2.9)
VVI pacing 1 (1.0)
Atrial lead positioned into
the right atrial appendage
98 (96.1)
Right ventricular lead
positioned at the right
ventricular apex
95 (96)
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(paroxysmal or chronic) and ﬁve patients had no pacemaker
interrogation with a programmer during follow-up. During
the follow-up period, one patient beneﬁted from a dual-
chamber to triple-chamber pacemaker upgrade due to HF.
Table 3 Pacemaker variables at the end of follow-up.
Pacemaker variable
Mean duration of pacemaker
follow-up between implantation
and last assessment (days)
670.6
Conventional DDD pacing 57 (55.9)
Dual-chamber minimal ventricular
pacing
28 (27.5)
DDI 2 (2)
AAI 5 (4.9)
VDD 1 (1)
VVI 9 (8.8)
Mean (median) percentage of atrial
stimulation before any progression
to chronic AF
68.4 (85)
Mean (median) percentage of
ventricular stimulation before any
56.3 (82.2)Data are mean± standard deviation or number (%).
irrespective of whether they needed hospitalization or only
ambulatory treatment adjustment for worsening HF. The
causes of death were classiﬁed as sudden death, death of
cardiac origin or other cause.
Statistical analysis
All analyses were performed according to the ‘‘intention-
to-treat’’ principle. Qualitative variables were analysed
using the Chi2 test or Fisher’s exact test when the number
of patients concerned was small (<5 for the theoreti-
cal population). Student’s t test or a unifactorial analysis
of variance was used to compare continuous variables.
Data not corresponding to a normal distribution (atrial
and ventricular stimulation rates and LVEF) were analysed
using a non-parametric test (Mann-Whitney test). Statisti-
cal signiﬁcance was concluded at P < 0.05 (95% conﬁdence
interval).
ResultsBetween 1 January 2001 and 31October 2006, 102medical
ﬁles met all inclusion criteria and these patients were
included in the study; their clinical characteristics at the
time of pacemaker implantation are summarized in Table 1.Rate-responsive pacing mode
activated
60 (58.9)
acemaker speciﬁcities and setting modes are summarized
n Table 2 .
ollow-up
o patient was lost to follow-up. The mean duration
f clinical follow-up was 806 days (i.e. approximately
.2 years), the minimum follow-up being 38 days and the
aximum 2043 days.
The pacemaker variables at the end of follow-up are
ummarized in Table 3. Events that occurred during the
ollow-up period are summarized in Table 4 .
Fifty-three patients (51.9%) had at least one episode of AFprogression to chronic AF
AF: atrial ﬁbrillation.
Data are number (%) unless otherwise indicated.
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Table 4 Events during follow-up.
Event
Paroxysmal AF not progressing to
chronic AF
34 (33.3)
Paroxysmal AF whether or not
progressing to chronic AF
47 (46.1)
Chronic AF whether or not preceded
by paroxysmal AF
19 (18.6)
Mean (median) time to progression to
chronic AF (days)
535 (391)
External electrical cardioversion 0 (0)
Episodes of heart failure 36 (35.3)
Cerebral embolism 5 (4.9)
Other systemic embolism 1 (1)
High-degree atrioventricular block 14 (13.7)
Deaths 29 (28.4)
Sudden death 5 (17.2)
Death of cardiac origin 8 (27.6)
Death from other cause 16 (55.2)
Mean (median) time to death after
pacemaker implantation (days)
598 (557)
Complete resolution of symptoms
after pacemaker implantation
74 (72.5)
Partial resolution of symptoms after
pacemaker implantation
21 (20.6)
No resolution of symptoms after
pacemaker implantation
7 (6.9)
AF: atrial ﬁbrillation.
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Among the 38 patients in whom the Holter pacemaker
ecordings could be determined unequivocally, 24 had their
ode of care changed on the basis of these recordings
anticoagulant treatment initiation, antiarrhythmic drug
eplacement or initiation).
hronic atrial ﬁbrillation
atients progressing to chronic AF (n = 19) had a higher HF
ncidence (P = 0.022). Neither the mode of pacing at the time
f pacemaker implantation nor the activation of algorithms
esigned to prevent AF had a signiﬁcant impact on the inci-
ence of chronic AF. All of these patients were treated with
itamin K antagonists (VKAs) at the end of the follow-up
eriod.
aroxysmal atrial ﬁbrillation
atients experiencing one or more episodes of documented
aroxysmal AF during follow-up (n = 47) had more frequently
history of AF before implantation (P = 0.022) and car-
iopathy of any kind of aetiology (P = 0.037) at the time of
acemaker implantation. A greater proportion of patients
n this group experienced one or more episodes of HF
P = 0.024); they also progressed more frequently to chronic
F (P = 0.03). In contrast, there were neither more deaths
or more thromboembolic events in this group. The pacing
ode did not affect the incidence of paroxysmal AF. With
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egard to patients who experienced an episode of paroxys-
al AF but did not progress to chronic AF, 67.6% received
t least transient treatment with VKA during follow-up and
2.9% were still being treated with VKAs at the end of
ollow-up. None of the treatments ongoing at the time of
mplantation or during follow-up (in particular angiotensin-
onverting enzyme inhibitors and angiotensin II receptor
lockers) were associated with a statistically signiﬁcant
ecrease in the number of paroxysmal AF episodes.
troke
ix patients (5.9%) experienced either cerebral or systemic
mbolism during follow-up. All of these patients had a
HADS2 score ≥2 [7]. Four of these patients presented
ocumented AF during follow-up, of whom two were not
eceiving anticoagulant treatment.
eart failure
atients experiencing HF during follow-up (n = 36) had a sig-
iﬁcantly lower LVEF at inclusion (mean 52.58 vs 62.97%,
< 0.001) and had more frequently ischaemic cardiac dis-
ase than another aetiology of cardiopathy (P = 0.002).
hese patients were classiﬁed more often in Killip class
II at the time of pacemaker implantation and were
eceiving beta-blocker treatment more often at this time.
onventional DDD mode [8] pacemaker programming at the
ime of implantation was a factor favouring HF (P = 0.026),
hereas dual-chamber minimal ventricular pacing was a
actor protecting against this event (P = 0.033). The ven-
ricular stimulation rate was signiﬁcantly higher in patients
resenting episodes of HF (mean 67.6%; median 96.7%)
han in those not experiencing this event (mean 50.6%,
edian 56.6%) (P = 0.044). Patients presenting HF episodes
uring follow-up also had more episodes of paroxysmal AF
P = 0.024) and chronic AF (P = 0.022), and had a higher mor-
ality (P < 0.001).
ortality
he patients who died during follow-up (n = 29) were
igniﬁcantly older (P = 0.033) and had more frequently
n LVEF ≤50% (P = 0.029) than those who survived. The
acemakers of patients who died were more often con-
entional dual-chamber pacemakers (P = 0.022) and less
ften dual-chamber minimal ventricular pacing pacemakers
P = 0.005). The ventricular stimulation rate was signiﬁcantly
igher among patients who died (mean 78.4%, median 98%)
han among those who remained alive (mean 49.4%; median
1%) (P = 0.039). This group also experienced more episodes
f HF (P < 0.001). In contrast, the rates of paroxysmal and
hronic AF did not differ between the two groups.
omparison of patients assigned to
onventional dual-chamber pacing and to
ual-chamber minimal ventricular pacings the development of pacemakers incorporating an algo-
ithm minimizing ventricular pacing occurred relatively
ecently, the duration of follow-up of patients who received
his type of device was signiﬁcantly shorter than that of
Pacem
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Table 5 Comparison of patients assigned to dual-chamber minimal ventricular pacing and to conventional dual-chamber pacing with a follow-up duration of
<1000 days.
Dual-chamber minimal
ventricular pacing
(n = 27)
Conventional DDD pacing
mode with a follow-up of
<1000 days
(n = 42)
P Relative risk
(conﬁdence interval)
Mean duration of follow-up (days) 480.6 567.4 0.215
Mena 7 (25.9) 18 (42.9) 0.153
Mean age± SD (years) 82.1± 3.6 83.2± 5.0 0.390
Sinus node dysfunction without history of AFa 10 (37.0) 23 (54.8) 0.150
Sinus node dysfunction with history of paroxysmal AFa 17 (63.0) 19 (45.2) 0.150
Mean LVEF at inclusion (%) 61.8, with 3 patients
(11.1%) having an LVEF
≤50%
57.8, with 13 patients
(31.0%) having an LVEF
≤50%
0.0670.057
First-degree atrioventricular blocka 7 (25.9) 16 (38.1) 0.295
Medicationa
Anticoagulant 14 (51.9) 14 (33.3) 0.126
Amiodarone 10 (37.0) 9 (21.4) 0.157
Flecainide 1 (3.7) 1 (2.4) 0.749
Propafenone 1 (3.7) 0 (0) 0.214
Sotalol 0 (0) 1 (2.4) 0.419
Other betablockers 9 (33.3) 10 (23.8) 0.387
Digoxin 0 (0) 4 (9.5) 0.098
Verapamil or diltiazem 0 (0) 2 (4.8) 0.250
ACE inhibitors or ARBs 15 (55.6) 23 (54.8) 0.948
Mean (median) ventricular stimulation rate before
possible chronic AF (%)
25.1 (2.5) 62.8 (86.0) 0.004
Patients with ventricular stimulation rate < 40% (%) 72.7 30.0 0.002
Episodes of heart failurea 5 (18.5) 19 (45.2) 0.023 2.23 (1.03—5.15)
Paroxysmal AF whether or not followed by chronic AFa 12 (44.4) 16 (38.1) 0.600
Chronic AFa 4 (14.8) 7 (16.7) 0.838
Systemic or cerebral embolisma 1 (3.7) 3 (7.1) 0.551
Deathsa 2 (7.4) 22 (52.4) <0.001 4.86 (1.24—19.07)
Sudden death 0 (0) 3 (7.1)
Sudden death, no. (%)
Death of cardiac origin 0 (0) 7 (16.7)
Death of cardiac origin
Death from other causes 2 (7.4) 12 (28.6)
Death from other cause, no. (%)
ACE: angiotensin-converting enzyme; AF: atrial ﬁbrillation; ARB: angiotensin receptor blocker; LVEF: left ventricular ejection fraction; SD: standard deviation.
a Data are number (%).
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Figure 1. Survival as a function of time according to pacing mode
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wn patients with a follow-up of less than 1000 days.
hose equipped with a conventional dual-chamber pace-
aker (480.6 days vs 919.9 days, P < 0.001). In order to
ompare these two groups of patients, we perfomed an
nalysis including only patients with a follow-up duration
f less than 1000 days. The main results of this analysis are
ummarized in Table 5, and Figs. 1 and 2.
igure 2. All-cause mortality and episodes of heart failure,
hronic AF and paroxysmal AF according to pacing mode among
atients with a follow-up of less than 1000 days. AF: atrial ﬁbril-
ation; NS: not signiﬁcant.
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iscussion
he population studied was composed of very old patients,
ith a mean (±standard deviation) age of 82.2 (±4.4)
ears; 67 patients (65.7%) were older than 80 years. To our
nowledge, this is the oldest population ever studied in trials
oncerning patients with sinus node dysfunction.
ymptoms
even patients (6.9%) showed no resolution of their symp-
oms and 21 patients (20.6%) achieved only partial symptom
esolution after pacemaker implantation. The symptoms of
inus node dysfunction are not speciﬁc to this pathology.
isorders such as vasovagal syncope and neurovestibular dis-
rders, which also occur very frequently among patients of
his age, can have similar symptoms. The multiple comor-
idities of elderly patients complicate the symptomatic
inus node dysfunction diagnosis.
trioventricular blocks
mong patients having sinus node dysfunction, the annual
ncidence of high-degree atrioventricular block has been
stimated to be 0.6 to 1.9% [9—12]. The European Society
f Cardiology [13] recommends the use of a single-chamber
trial pacemaker (Class I indication, level of evidenceC) in
atients with sinus node dysfunction alone (i.e. not asso-
iated with arrhythmia or a conduction disorder). In our
tudy, the rate of high-degree atrioventricular block was
stimated to be 13.7% during a mean follow-up of 2.2 years,
orresponding to an annual incidence of 6.2%. Our incidence
as higher than those previously described [9—12], probably
ecause our patient population was older than those in these
rials but also because we did not perform atrial-pacing tests
o evaluate atrioventricular conduction before inclusion,
nlike the studies from which these low atrioventricular
lock incidences are extracted.
trial ﬁbrillation
he annual incidence of chronic AF during follow-up in our
tudy (8.5%) was higher than those reported in other trials:
.7% in MOST [1]; 3.25% in CTOPP [2]; and 6.1% in SAVE PACe
4]. This increase in chronic AF incidence with age should be
aken into account when choosing the pacing mode and the
ype of pacemaker to be implanted.
The age of a patient is generally recognized to be a risk
actor for progression to chronic AF [14,15]. However, in our
tudy, mean age did not differ signiﬁcantly between patients
ho progressed to chronic AF and those who did not. The
ame applied to patients who experienced paroxysmal AF
ompared with those who did not. This may be explained
y the difﬁculty of detecting an age difference between
wo groups of patients within a population comprising exclu-
ively elderly patients, with a mean age of 82.2 years and a
arrow standard deviation (±4.4). Surprisingly, no electrical
ardioversion was reported to treat persistent AF, despite
he high prevalence of HF; this may be explained by a pre-
erred rate-control strategy in elderly patients.
Among the patients who experienced an episode of parox-
smal AF without subsequently progressing to chronic AF,
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only 67.6% had received at least transient treatment with
VKAs and only 52.9% were still receiving VKAs at the end
of follow-up, despite 82.4% of these patients having (had) a
CHADS2 score ≥ 2 [7] at inclusion. In contrast, all patients
who developed chronic AF received at least transient treat-
ment with VKAs, despite the risk of stroke being considered
equivalent in these two types of AF in all recommendations
[16].
No particular pacing mode programmed at the time of
implantation (and at the end of follow-up) was signiﬁ-
cantly associated with an increase or decrease in the risk
of paroxysmal or chronic AF. Several studies have shown a
difference in the incidence of chronic AF according to the
pacing mode [1,2,10] but all of these trials compared the
VVI mode with other pacing modes. The SAVE PACe trial [4]
revealed a 40% decrease in the relative risk of developing
chronic AF in patients assigned to dual-chamber minimal
pacing compared with those assigned to conventional dual-
chamber pacing. But in terms of absolute risk, the decrease
was only 2.8% per year, indicating that 36 patients needed to
be treated to prevent one case of chronic AF per year. This
difference in progression to chronic AF in the SAVE PACe
trial [4] was attributed to a lower ventricular stimulation
rate in the group of patients whose pacemakers incorpo-
rated an algorithm minimizing ventricular pacing (median
9.1% vs 99% in the other group). In our study, the median
ventricular rate in the group with a pacemaker incorporat-
ing such an algorithm was 2.5% (before any progression to
chronic AF) compared with a median of 95.5% in the group
of patients whose pacemaker did not include this algorithm
(P < 0.001). On this basis, we may conclude that this algo-
rithm remains an effective means of reducing the ventricular
stimulation rate in patients aged over 75 years, although the
incidence of AF (paroxysmal and chronic) was not affected
by the pacing mode to a statistically signiﬁcant extent in our
study (at least within the implemented follow-up period).
Heart failure
During follow-up, 36 patients (35.3%) experienced HF,
corresponding to an annual incidence of 16%. Among these
patients, we noted higher event rates for both chronic AF
(P = 0.022) and paroxysmal AF (P = 0.024). This ﬁnding is
consistent with the results of the SAVE PACe trial [4], in
which patients who presented persistent AF had a higher
rate of hospitalizations for HF (P = 0.03).
In the MOST trial [17], in the group of patients with a dual-
chamber pacemaker, a ventricular stimulation rate above
40% was correlated with a relative risk of hospitalization for
HF 2.6-fold higher than that in patients with a ventricular
stimulation rate below 40%. Similarly, in our study, the ven-
tricular stimulation rate was signiﬁcantly lower (P = 0.044)
in patients who did not experience any episode of HF
(mean 50.6%; median 56.6%) than in the group of patients
presenting HF, irrespective of whether or not this event
necessitated hospitalization (mean 67.6%; median 96.7%).
As already mentioned, the ventricular stimulation rate was
signiﬁcantly reduced by algorithms minimizing ventricular
pacing. It is, therefore, logical that the group of patients
experiencing HF included fewer patients assigned to dual-
chamber minimal ventricular pacing (P = 0.03) and more
patients assigned to conventional dual-chamber pacing.
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As pacemakers with algorithms minimizing ventricu-
ar stimulation have been developed only recently, the
atients with this type of pacemaker had a shorter follow-
p compared with other patients (P < 0.001). But as the
ide-effects of right ventricular stimulation often develop
lowly (in the MOST trial, for example, the risk of HF due
o ventricular pacing was mainly evident from 5 years of
ollow-up onwards [18]), a signiﬁcant difference in dura-
ion of follow-up would have created bias in our study. That
s why we analysed a subgroup of patients with a follow-
p period of less than 1000 days. In this substudy, with a
omparable follow-up period (P = 0.21), the incidence of HF
as still signiﬁcantly lower in the group of patients assigned
o dual-chamber minimal ventricular pacing than in patients
ssigned to conventional dual-chamber pacing (P = 0.023).
The relative risk of HF in patients with a conventional DDD
acemaker, compared with in those with a pacemaker incor-
orating an algorithm minimizing ventricular stimulation,
as estimated to be 2.23 (conﬁdence interval 1.03—5.15). In
he SAVE PACe trial [4], no such difference was observed, but
he mean age of the patients was lower (72.3 years in SAVE
ACe vs 82.7 years in our study). It may, therefore, be pos-
ulated that the older the patient, the lower the tolerance
f right ventricular stimulation, probably due to a greater
ecrease in left ventricular compliance in older patients.
ortality
n our study, 29 patients (28.4%) died, corresponding to an
nnual mortality rate of 12.9%, with a mean time to death of
98 days post-implantation. In a substudy of MOST [19], the
-year mortality of patients aged over 75 years was 23.5%.
n our study, 17.2% of deaths were sudden deaths, 27.6%
ere of cardiac origin and 55.2% were due to other causes.
hese proportions are fairly similar to those reported in
OST [19].
Among patients with a follow-up of less than 1000 days,
omparison of those assigned to conventional dual-chamber
acing with those assigned to dual-chamber minimal ven-
ricular pacing revealed a lower mortality in the latter
roup (P < 0.001). The relative risk of death between these
wo groups was estimated to be 4.86 (conﬁdence interval
.24—19.07). This indicated that death can occur relatively
oon after implantation in the group of patients receiving
conventional DDD pacemaker, as the difference between
he groups was statistically signiﬁcant despite the limited
uration of follow-up. No such difference was observed in
he SAVE PACe trial [4], but as mentioned earlier, the mean
ge of the patients was lower (72.3 years in SAVE PACe vs
2.7 years in our study), which may partly explain this dif-
erence.
tudy limitations
his was a retrospective, observational study. At inclu-
ion, 27 patients had a pacemaker in which the algorithm
inimizing ventricular pacing was activated, whereas
1 patients had a conventional DDD pacemaker. It is con-
eivable that the choice of a pacemaker incorporating an
lgorithm minimizing ventricular stimulation might have
een made on the basis of the patient’s general state of
ealth. This could partly explain the difference in non-
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ardiac mortality between the two groups (even if the
roups characteristics were not statistically different at
nclusion).
The duration of our study (like that of most trials focusing
n this topic) was relatively short (mean follow-up 806 days).
et the time elapsing between pacemaker implantation and
he development of complications related to this proce-
ure, such as HF, embolic complications or progression to
hronic AF, is often lengthy. Such relatively long delays in
he onset of complications may be considered to be fully
cceptable in patients aged over 75 years, but do not nec-
ssarily apply to this patient population; in our study, even
shorter follow-up was sufﬁcient to reveal statistically sig-
iﬁcant differences in the incidences of HF episodes and
ortality. The complications of right ventricular stimula-
ion seem to occur faster in elderly patients than in younger
atients.
onclusion
ortality and morbidity are both high among patients who
eceive a pacemaker in the context of sinus node dysfunc-
ion. Dual-chamber pacemakers incorporating an algorithm
inimizing ventricular stimulation appear to reduce the
umber of HF episodes and deaths in patients aged over
5 years with sinus node dysfunction. This ﬁnding warrants
he implantation of such devices, even in patients of this
ge group.
onﬂicts of interest statement
one.
unding: This study was not supported by any manufacturer.
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